BioLife Solutions Inc (BLFS)Healthcare | Medical Instruments & Supplies | Bothell, United States | NasdaqCM
38.61 USD
|
Hot Take ↕ | Oct. 10, 2026, 8:29 a.m. EDT
The investment thesis here is entirely driven by the imminent $1.5 billion acquisition by Repligen, which transforms this from a speculative biotech play into a high-probability arbitrage vehicle. While the company's standalone fundamentals are weak—showing a massive forward P/E of 117x and negligible long-term growth—the pending sale provides a clear price floor and a catalyst for the stock to trade closer to the deal value. The options market confirms this sentiment with aggressive call buying and zero hedging, suggesting traders expect the price to rise toward the deal terms before closing. However, investors must remain vigilant regarding the announced fairness probes and class-action investigations, which could introduce regulatory delays or legal costs that complicate the timeline. For now, the risk-reward profile is skewed heavily toward the upside due to the certainty of the sale, making it a compelling short-to-intermediate hold despite the lack of organic business quality. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.747 |
| Revenue per Share | 2.207 |
| Market Cap | 1,888,929,920 |
| Trailing P/E | 39.00 |
| Forward P/E | 117.00 |
| Beta | 1.82 |
| Profit Margins | 54.35% |
| Website | https://www.biolifesolutions.com |
As of Oct. 10, 2026, 8:29 a.m. EDT: Speculators are overwhelmingly bullish, positioning heavy call volume and open interest at strikes above the current price ($40, $50) while virtually ignoring put protection. Implied volatility is extremely compressed for calls (near zero), indicating a lack of fear and a strong expectation of a gap-up or steady rally. The absence of meaningful put activity suggests the market views downside risk as negligible in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.39235485 |
| Address1 | 3,303 Monte Villa Parkway |
| Address2 | Suite 310 |
| All Time High | 60.669 |
| All Time Low | 0.139999 |
| Ask | 47.06 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 1,332,401 |
| Average Daily Volume3 Month | 1,164,074 |
| Average Volume | 1,164,074 |
| Average Volume10Days | 1,332,401 |
| Beta | 1.824 |
| Bid | 27.79 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 8.591 |
| City | Bothell |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 38.61 |
| Current Ratio | 9.694 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,789,430,400 |
| Day High | 38.83 |
| Day Low | 36.96 |
| Debt To Equity | 3.747 |
| Display Name | BioLife |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | 6,900,000 |
| Ebitda Margins | 0.06467 |
| Enterprise To Ebitda | 264.001 |
| Enterprise To Revenue | 17.074 |
| Enterprise Value | 1,821,609,856 |
| Eps Current Year | 0.25 |
| Eps Forward | 0.33 |
| Eps Trailing Twelve Months | 0.99 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 425 402 1433 |
| Fifty Day Average | 36.0792 |
| Fifty Day Average Change | 2.5307999 |
| Fifty Day Average Change Percent | 0.070145674 |
| Fifty Two Week Change Percent | 39.235485 |
| Fifty Two Week High | 39.76 |
| Fifty Two Week High Change | -1.1499977 |
| Fifty Two Week High Change Percent | -0.028923485 |
| Fifty Two Week Low | 17.86 |
| Fifty Two Week Low Change | 20.75 |
| Fifty Two Week Low Change Percent | 1.1618141 |
| Fifty Two Week Range | 17.86 - 39.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 946,909,800,000 |
| Float Shares | 40,123,549 |
| Forward Eps | 0.33 |
| Forward P E | 117.0 |
| Free Cashflow | 4,664,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 155 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 38.61 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.63613 |
| Gross Profits | 67,867,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02606 |
| Held Percent Institutions | 1.05511 |
| Implied Shares Outstanding | 48,923,333 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,390,953,600 |
| Last Split Factor | 1:14 |
| Long Business Summary | BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington. |
| Long Name | BioLife Solutions Inc |
| Market | us_market |
| Market Cap | 1,888,929,920 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_265126 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 49,210,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,844,898,887 |
| Number Of Analyst Opinions | 4 |
| Open | 0.0 |
| Operating Cashflow | 16,877,000 |
| Operating Margins | 0.059580002 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 15.09 |
| Phone | 425 402 1400 |
| Previous Close | 38.61 |
| Price Eps Current Year | 154.44 |
| Price Hint | 2 |
| Price To Book | 4.4942384 |
| Price To Sales Trailing12 Months | 17.705177 |
| Profit Margins | 0.54346 |
| Quick Ratio | 6.673 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 38.83 |
| Regular Market Day Low | 36.96 |
| Regular Market Day Range | 36.96 - 38.83 |
| Regular Market Open | 0.0 |
| Regular Market Previous Close | 38.61 |
| Regular Market Price | 38.61 |
| Regular Market Time | 1,791,230,402 |
| Regular Market Volume | 0 |
| Return On Assets | 0.00262 |
| Return On Equity | 0.12829 |
| Revenue Growth | 0.215 |
| Revenue Per Share | 2.207 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 48,923,333 |
| Shares Percent Shares Out | 0.0794 |
| Shares Short | 3,884,193 |
| Shares Short Previous Month Date | 1,786,665,600 |
| Shares Short Prior Month | 4,017,528 |
| Short Name | BioLife Solutions, Inc. |
| Short Percent Of Float | 0.1082 |
| Short Ratio | 4.54 |
| Source Interval | 15 |
| State | WA |
| Symbol | BLFS |
| Target High Price | 31.0 |
| Target Low Price | 31.0 |
| Target Mean Price | 31.0 |
| Target Median Price | 31.0 |
| Total Cash | 82,416,000 |
| Total Cash Per Share | 1.685 |
| Total Debt | 15,738,000 |
| Total Revenue | 106,688,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.99 |
| Trailing P E | 39.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.772675 |
| Two Hundred Day Average Change | 11.837326 |
| Two Hundred Day Average Change Percent | 0.44214207 |
| Type Disp | Equity |
| Volume | 0 |
| Website | https://www.biolifesolutions.com |
| Zip | 98,021 |